United StatesÚltimas notícias

Innoviva (NASDAQ:INVA) partnered with Dr. Reddy’s Laboratories (NYSE:RDY) to commercialize antibiotic XACDURO across four international territories.

One Stop Systems (NASDAQ:OSS) announced an initial $8.4 million defense contract to supply high-performance computing servers.

Yum! Brands (NYSE:YUM) executed definitive agreements to sell its Pizza Hut restaurant brand for $2.7 billion in the aggregate.

Allergan Aesthetics (NYSE:ABBV) received U.S. FDA approval for SKINVIVE neck treatments as its second product indication.

Swvl Holdings (NASDAQ:SWVL) announced its financial results for the three months ended March 31, 2026, revealing a substantial 68% year-over-year increase in total revenue to $8.2M.

Dan Ives, global senior equity analyst at Wedbush Securities, discusses what he calls the "tug of war" between Anthropic and the Trump administration, why he expects accelerated M&A on artificial intelligence, and reported losses at OpenAI ahead of the company's IPO later this year.

Clinical-stage biotech company Clearmind Medicine (NASDAQ:CMND) has successfully completed the dosing of all 24 healthy participants in Part A of its FDA-regulated Phase I/II trial evaluating its proprietary compound, CMND-100, for the treatment of Alcohol Use Disorder.

"What the market wants to see is evidence that the Bank of Japan is not behind the curve on inflation," says Jane Foley, head of FX strategy at Rabobank, as the BOJ raised its benchmark interest rate by a quarter percentage point to 1%.

Solana Company (NASDAQ:HSDT) rejected an unsolicited all-stock acquisition proposal from Forward Industries (NASDAQ:FWDI) valuing the business at $1.48 per share.

Clinical-stage biopharmaceutical firm HCW Biologics (NASDAQ:HCWB) reported positive preliminary human data from its Phase 1 trial of HCW9302, revealing that all three mild alopecia areata patients in the 3 μg/kg cohort achieved a 25% or greater reduction in SALT scores.

NovaBridge Biosciences (NASDAQ:NBP) received FDA Fast Track Designation for its bispecific antibody givastomig to treat advanced gastric adenocarcinoma expressing Claudin 18.2 protein levels.

Trinity Biotech (NASDAQ:TRIB) secured new purchase orders for over 2 million HIV tests to support its annual financial objectives.